Efficacy of inhaled DNase in admitted infants with RSV-bronchiolitis

Completed

• Conditions: Bronchiolitis, RSV-bronchiolitis; Respiratory; Acute bronchiolitis

• Registration Number: ISRCTN92577199
• Lead Sponsor: Roche Nederland BV (Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-12
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 222

Inclusion Criteria

1. RSV bronchiolitis with need for additional oxygen (saturation iÜ 92 %)
2. RSV-infection proven with rapid assay or culture
3. Age < 12 months
4. Admission on (medium care) ward
5. Study medication can be started within 24 hours

Exclusion Criteria

1. Premature birth (born < 32 weeks of gestation)
2. Congenital heart disease
3. Pre-existent lung disease (e.g. BPD or CF)
4. T-cel immune deficiency
5. Pre-treatment with systemic steroids

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Length of stay <br>2. Symptom score

Secondary Outcome Measures

Name	Time	Method
1. Duration of oxygen supplementation<br>2. Need for ICU-admission<br>